Within 3 months of treatment, complete haematological response anti-CML (CHR, Fig. 1A) and >2log reduction of BCR-ABL1/ABL1 ratio (down to 0.73%) were achieved albeit persistent lymphocytosis occurred (PB lymphocyte count >5.0 × 109/L, Fig. 1A). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.